Publications
Wang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL, Kenfield SA. Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR cancer. 2023. PMID: 37261885
Laura Ann Huppert, Elene Tsopurashvili, Sai Sahitha Somepalle, Amy Jo Chien, Melanie Majure, Hope S. Rugo, Ronald Balassanian, Michelle E. Melisko. Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: A single center retrospective cohort study. Journal of Clinical Oncology. 2023. PMID:
Wang EY, Borno HT, Washington Iii SL, Friedlander T, Zhang S, Trejo E, Van Blarigan EL, Chan JM, Shariff-Marco S, Beatty AL, Kenfield SA. Engaging Men of Diverse Racial and Ethnic Groups With Advanced Prostate Cancer in the Design of an mHealth Diet and Exercise Intervention: Focus Group Study. JMIR cancer. 2023. PMID: 37261885
Laura Ann Huppert, Amelia S Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Alexander Cheung, Mark M. Moasser, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Pamela N. Munster, Michael J. Campbell, Lawrence Fong, Amy Jo Chien. Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC). Journal of Clinical Oncology. 2023. PMID:
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37308125
Howard Jinsoo Lee, Louise Christie Walter, Alexander K. Smith, Ying Shi, W. John Boscardin, Harvey Jay Cohen, Grant Richard Williams, Sandra Zeng, Carolyn J Presley, Allison Magnuson, Supriya Gupta Mohile, Surbhi Singhal, Carling Jade Ursem, Ana I. Velazquez Manana, Matthew A. Gubens, Collin M. Blakely, Claire Mulvey, Greg M. Allen, Jonathan Ostrem, Melisa L. Wong. Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy. Journal of Clinical Oncology. 2023. PMID:
Catherine Choy Smith, Pankit Vachhani, Guillermo Garcia-Manero, Nicole Renee Grieselhuber, Guru Subramanian Guru Murthy, Astha Bhatia, Jatinder Arora, Hooman Izadi, Anthony Fiorino, Raajit Rampal. A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML). Journal of Clinical Oncology. 2023. PMID:
Jacqueline V. Aredo, Anatoly Urisman, Matthew A. Gubens, Claire Mulvey, Greg M. Allen, Julia K. Rotow, Daniel Lucas Kerr, Turja Chakrabarti, Bianca Bacaltos, Megan Gee, Kirk Jones, Dara L. Aisner, Tejas Patil, Erin Lynn Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes Ruediger Kratz, David Jablons, Collin M. Blakely. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer. Journal of Clinical Oncology. 2023. PMID:
Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, Lai JC, Grover S, Zucker SD. Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor-Induced Hepatitis. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37308118
Edward Maldonado, Thomas A. Hope, Rahul Raj Aggarwal, Daniel H Kwon, Li Zhang, Kelly Gordon, Barry Tong, Adina Bailey, Vipul Kumar, Ivan de Kouchkovsky, Vadim S Koshkin, Hala Borno, Jonathan Chou, Rohit Bose, Lawrence Fong, Arpita Desai, Terence W. Friedlander, Eric Jay Small. Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET. Journal of Clinical Oncology. 2023. PMID:
Chang R, Gulley JL, Fong L. Vaccinating against cancer: getting to prime time. Journal for immunotherapy of cancer. 2023. PMID: 37286302
Alberto Carretero-González, Daniel Kwon, Nonna Shakhnazaryan, Julian C. Hong, Osama Mohamad, Mary Uan-Sian Feng, Ivan de Kouchkovsky, Hala Borno, Rohit Bose, Jonathan Chou, Arpita Desai, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin, Felix Y Feng, Rahul Raj Aggarwal, Thomas A. Hope, Eric Jay Small. Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging. Journal of Clinical Oncology. 2023. PMID:
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2023. PMID: 37269841
Douglas MP, Ragavan MV, Chen C, Kumar A, Gray SW, Blakely CM, Phillips KA. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. Journal of the National Comprehensive Cancer Network : JNCCN. 2023. PMID: 37308126
Cheng ML, Huang Y, Luong N, LoPiccolo J, Nishino M, Sholl LM, Chirieac LR, Santucci AD, Rabin MS, Jänne PA, Coker S, Diamond JR, Hilton J, Shapiro GI, French CA. Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation. JCO precision oncology. 2023. PMID: 37384867
Raffit Hassan, Marcus O. Butler, David Yoonsuk Oh, Roisin Eilish O'Cearbhaill, Lauren MacMullen, Erin Jeter, Udayan Guha, Viera P. Muzithras, Kevin Zikaras, Melissa Lynne Johnson, Janos Laszlo Tanyi, Azam Ghafoor, Robert Tighe, Munisha Smalley, Alfonso Quintas-Cardama, David S. Hong. Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors. Journal of Clinical Oncology. 2023. PMID:
Dutta R, Vallurupalli M, McVeigh Q, Huang FW, Rebbeck TR. Understanding inequities in precision oncology diagnostics. Nature cancer. 2023. PMID: 37248397
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. British journal of haematology. 2023. PMID: 37246588
Tulpule A, Menon S, Breese M, Lin Y, Allegakoen H, Perati S, Heslin A, Horlbeck M, Weissman J, Sweet-Cordero A, Bivona T. FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer. Research square. 2023. PMID: 37398210
Tsang ES, Munster PN. Vaccinia (Smallpox) for the Treatment of Ovarian Cancer-Turning an Old Foe Into a Friend? JAMA oncology. 2023. PMID: 37227718